91ÊÓƵרÇø

²â´Ç³Ü²â¾±³ú³ó´Ç²Ô²µ»å¾±³æ¾±£¬²õ³ó¾±²ú³Ü³Ù²¹¾±Âá¾±²¹²Ô²â¾±»å±ð£¬Âá¾±³Ü²õ³ó¾±³ú³ó±ð²Ô»å³Ü¾±²ú²¹´Ç±ô±ð¾±²µ±ð²µ³Ü»å±ð¡£»å²¹³¾¾±²Ô²µ³¦³ó´Ç²Ô²µ³ú³Ü´ÇÂá¾±³Ü²Ô¾±²¹²Ô£¬²â±ð²õ³ó¾±³¾²¹²Ô±ç¾±²Ô²µ³¦³ó´Ç²Ô²µ»å±ð²â³Ü²¹²Ô²Ô¾±²¹²Ô£¬³ú²¹¾±³ú³ó±ð²â¾±²Ô¾±²¹²Ô£¬²µ²¹²Ô²µ²µ²¹²Ô²µ»å±ð²Ô²µÂá¾±»å±ð³ó³Ü²¹²Ô²µ³Ù²¹¾±Âá¾±²â¾±Âá¾±²Ô²µ³¦³ó´Ç²Ô²µ´Ú±ð²Ô²â¾±²õ³ó¾±»å²¹´Ç£¬²â²¹´Ç³æ¾±²¹²Ô²µ³¦³ó±ð»å¾±Âá¾±²ú²¹¾±»å²¹³¾¾±²Ô²µÂá¾±³Ü²ú¾±³æ³Ü±ç³Ü±ð²ú²¹´Ç³ó´Ç³Ü´Ú²¹²Ô²µ·É±ð²Ô»å¾±²Ô²µ£¬±ð°ù²â²¹´Ç³æ¾±²¹²Ô²µ·É±ð²Ô»å¾±²Ô²µ³ó´Ç³Ü´Ú²¹²Ô²µ£¬Âá¾±³Ü°ì´Ç²Ô²µ³ú³ó¾±³¦³ó²¹´Ç³æ¾±²¹²Ô£¬²â³Ü²õ³ó¾±³ú²¹¾±³ú³ó±ð²â¾±²Ô¾±²¹²Ô²ú²¹²â³Ü±ð£¬44²õ³Ü¾±»å±ð³ó³Ü²¹²Ô²µ³Ù²¹¾±Âá¾±²â³ÜÂá¾±²¹±ç¾±²Ô³ú³ó±ð²Ô²µ£¬»å²¹¾±²ú¾±²Ô²µ²µ´Ç²Ô²µ»å²¹³¦³ó²¹´Ç³æ¾±²¹²Ô¡£Âá¾±±ð²µ³Ü´ÇÂá¾±³Ü²õ³ó¾±³¦³ó²¹´Ç³æ¾±²¹²Ô°ù±ð²Ô³ú³Ü»å²¹·É²¹²Ô²µ²â¾±»å³Ü²¹²ÔÂá³Ü±ð³ó±ð³¾¾±²Ô²µ³¦³ó²¹´Ç»å±ð²µ³Ü²¹²Ô³æ¾±£¬³¦³ó±ð»å¾±²µ³Ü¾±²õ³ó³Ü²Ô»å²¹±ç¾±²Ô²µ·É±ð¾±Âá¾±±ðÂá³Ü¡£

ºþ(±á³Ü)ÄÏ(±·²¹²Ô)½»(´³¾±²¹´Ç)ͨ(°Õ´Ç²Ô²µ)¹¤(³Ò´Ç²Ô²µ)³Ì(°ä³ó±ð²Ô²µ)ѧ(³Ý³Ü±ð)Ôº(³Û³Ü²¹²Ô)ÕÙ(´Ü³ó²¹´Ç)¿ª(°­²¹¾±)2024Äê(±·¾±²¹²Ô)ÉÏ(³§³ó²¹²Ô²µ)ѧ(³Ý³Ü±ð)ÆÚ(²Ï¾±)ÆÚ(²Ï¾±)Ä©(²Ñ´Ç)ʳ(³§³ó¾±)Æ·(±Ê¾±²Ô)°²(´¡²Ô)È«(²Ï³Ü²¹²Ô)¹¤(³Ò´Ç²Ô²µ)×÷(´Ü³Ü´Ç)»á(±á³Ü¾±)Òé(³Û¾±)

²â³Ü°ì²¹²Ô²µ³ú³Ü´Ç·É³Ü´Ú²¹±ç¾±²Ô±ô¾±²Ô²â¾±²õ³ó¾±³æ¾±²¹²Ô³¦³ó²¹²Ô²µ³ú³Ü¾±³ú³ó´Ç²Ô²µ²â²¹´Ç»å±ð²õ³ó¾±£¬³ú²¹¾±²µ²¹´Ç²µ³Ü²¹²Ô²µ²õ³ó¾±°ì±ð£¬³Ù²¹³¾±ð²Ô±è³Ü²ú¾±²¹²Ô°ù±ð²Ô·É±ð¾±Âá¾±²Ô°ù´Ç²Ô²µ³æ¾±²Ô²µ²â±ðÂá¾±³Ü²õ³ó¾±²ú³Ü³¾¾±±ð»å±ð»å±ð²Ô²µ³Ù²¹£¬±ð°ù³Ù²¹³¾±ð²ÔÂá¾±³Ü²õ³ó¾±³ú³ó²¹²Ô³ú²¹¾±³Ù²¹Âá¾±²¹²Ô»å±ð²Ô²¹²â¾±³æ¾±²¹´Ç²ú³Ü´Ú±ð²Ô°ù±ð²Ô¡£

Ö¾(´Ü³ó¾±)ºÀ(±á²¹´Ç)̧(°Õ²¹¾±)Æð(²Ï¾±)ƨ(±Ê¾±)¹É(³Ò³Ü)Àë(³¢¾±)¿ª(°­²¹¾±)×ù(´Ü³Ü´Ç)λ(°Â±ð¾±)£¬¹Ê(³Ò³Ü)Òâ(³Û¾±)°Ñ(µþ²¹)С(³Ý¾±²¹´Ç)µÊ(¶Ù±ð²Ô²µ)×Ó(´Ü¾±)Ū(±·´Ç²Ô²µ)³ö(°ä³ó³Ü)Éù(³§³ó±ð²Ô²µ)£¬ÊÔ(³§³ó¾±)ͼ(°Õ³Ü)ת(´Ü³ó³Ü²¹²Ô)ÒÆ(³Û¾±)µÂ(¶Ù±ð)ɽ(³§³ó²¹²Ô)µÄ(¶Ù±ð)×¢(´Ü³ó³Ü)Òâ(³Û¾±)¡£µÂ(¶Ù±ð)ɽ(³§³ó²¹²Ô)ɨ(³§²¹´Ç)ÁË(³¢¾±²¹´Ç)Ò»(³Û¾±)ÑÛ(³Û²¹²Ô)Ö¾(´Ü³ó¾±)ºÀ(±á²¹´Ç)Ö®(´Ü³ó¾±)ºó(±á´Ç³Ü)£¬ÓÖ(³Û´Ç³Ü)Èá(¸é´Ç³Ü)Èá(¸é´Ç³Ü)µØ(¶Ù¾±)¿´(°­²¹²Ô)ÁË(³¢¾±²¹´Ç)¿´(°­²¹²Ô)ÎÒ(°Â´Ç)£¬°Ñ(µþ²¹)ÑÌ(³Û²¹²Ô)Í·(°Õ´Ç³Ü)ÔÚ(´Ü²¹¾±)ÑÌ(³Û²¹²Ô)»Ò(±á³Ü¾±)¸×(³Ò²¹²Ô²µ)Æþ(²Ï¾±²¹)Ãð(²Ñ¾±±ð)ÁË(³¢¾±²¹´Ç)¡£¸ù(³Ò±ð²Ô)±¾(µþ±ð²Ô)û(²Ñ±ð¾±)ÓÐ(³Û´Ç³Ü)Ìå(°Õ¾±)»á(±á³Ü¾±)µ½(¶Ù²¹´Ç)Ö¾(´Ü³ó¾±)ºÀ(±á²¹´Ç)Õù(´Ü³ó±ð²Ô²µ)·ç(¹ó±ð²Ô²µ)³Ô(°ä³ó¾±)´×(°ä³Ü)µÄ(¶Ù±ð)ÐÄ(³Ý¾±²Ô)Àí(³¢¾±)¡£

ÈçºÎÇø·Ö·ÇµäÐÍCMLÓëÆäËû¹ÇËèÔöÖ³ÐÔÖ×ÁöÔ­´´2020-09-12 17:53¡¤Ò½ÂöͨѪҺ¿Æ×÷ÕߣºÀ¶¾¨Ïþ»¢±¾ÎÄΪ×÷ÕßÊÚȨҽÂöͨ·¢²¼£¬Î´¾­ÊÚȨÇëÎðתÔØ¡£·ÇµäÐÍÂýÐÔËèϵ°×Ѫ²¡(aCML)£¬BCR-ABL1(£­)£¬ÊÇÒ»ÖÖº±¼ûµÄѪҺ¶ñÐÔÖ×Áö£¬ÊôÓÚWHO¹ÇËèÖ×Áö·ÖÀàÖеĹÇËèÔöÉúÒì³£/¹ÇËèÔöÖ³ÐÔÖ×Áö(MDS/MPN)¡£aCML×î³õ±»ÃüÃûΪ¡°·ÇµäÐÍ¡±ÐÎʽµÄÂýÐÔËèϵ°×Ѫ²¡(CML)£¬¼¸Ê®ÄêÀ´aCMLµÄÕï¶Ï±ê×¼·¢ÉúÁËÏÔÖø±ä»¯¡£È»¶ø£¬aCMLµÄÕï¶Ïȱ·¦ÌØÕ÷ÐÔ£¬¶ÔÆä·Ö×Ó»ùÒòͼÆ×µÄÈÕÒæÁ˽âÓÐÖúÓÚÇø·ÖaCMLÓëÆäËûMDS/MPNºÍMPNs£¬ÒÔ±ãÔçÆÚÆô¶¯ÖÎÁƺ͸ÄÉÆÔ¤ºó¡£aCMLµÄÁÙ´²ºÍÐÎ̬±íÐÍaCML»¼Õß±íÏÖ³ö¹ÇËèÔöÉúÌØÕ÷£¬°üÀ¨°×ϸ°ûÔö¶àºÍÆ¢Ö״󣬿ɰéÓÐƶѪºÍѪС°å¼õÉÙ¡£WBC¼ÆÊý¡Ý13¡Á109/L¡£ÍâÖÜѪÖдæÔÚÖÁÉÙ10%µÄδ³ÉÊìÁ£Ï¸°û£¨°üÀ¨ÔçÓ×Á£Ï¸°û¡¢ÖÐÓ×Á£Ï¸°ûºÍÍíÓ×Á£Ï¸°û£©£¬ÒÔÖضÈÁ£Ï¸°ûÉú³ÉÕÏ°­ÎªÌØÕ÷¡£²»´æÔÚµ¥ºËϸ°ûÔö¶à£¨ÍâÖÜѪµ¥ºËϸ°û<ѪҺ°×ϸ°ûµÄ10%£¬ÑªÒº¼ÆÊý< 1¡Á109/L£©ÍâÖÜѪÖеÄÊȼîÐÔÁ£Ï¸°û< 2%¡£¹ÇËèºÍÍâÖÜѪÖÐԭʼϸ°û£¨°üÀ¨Ó×µ¥ºËϸ°û£©< 20%¡£ÐÎ̬ѧÉÏ£¬aCMLÍâÖÜѪ±íÏÖΪÑÏÖØÁ£Ï¸°ûÒìÐÍÔöÉú¡£ÌØÕ÷ÐÔ±íÏÖ°üÀ¨ÖÐÐÔÁ£Ï¸°ûµÄȾɫÖʹý¶È¾Û¼¯ÒÔ¼°ºË·ÖÁÑÏóÒì³££¬ÈçºËµÍ·ÖÒ¶(¼ÙPelger-HuetºË)»ò¶à·ÖÒ¶¡£°û½¬¿É³Ê¿ÅÁ£¼õÉÙÉõÖÁÒì³£Ôö´ó¡£¹ÇËèϸ°û¹ý¶à£¬ÒÔÁ£Ï¸°ûΪÖ÷£¬³ÊÃ÷ÏÔÒìÐÍÔöÉú¡£°ëÊýÒÔÉϲ¡ÀýÓкìϵ·¢Óý²»Á¼ºÍÒ»¶¨³Ì¶ÈµÄ¾ÞºËϸ°û·¢Óý²»Á¼¡£´ËÍ⣬¿É¼û²»Í¬³Ì¶ÈµÄÍøÓ²µ°°×ÏËάÔö¼Ó¡£WHO 2016ÄêÌá³öµÄaCMLÒÔ¼°¾ßÓÐÏàËÆÌØÕ÷µÄËèϵÖ×ÁöÕï¶Ï±ê×¼×ܽá¼ûÏÂ±í¡£×¢£ºaCML£¬·ÇµäÐÍÂýÐÔËèÐÔ°×Ѫ²¡£»BM£¬¹ÇË裻CMML£¬ÂýÐÔÁ£µ¥ºËϸ°û°×Ѫ²¡£»ET£¬Ô­·¢ÐÔѪС°åÔö¶àÖ¢£»MDS/MPN-RS-T£¬¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö°é»·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àÖ¢£»MDS/MPN-U£¬¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö£¬²»¿É·ÖÀࣻPV£¬ÕæÐÔºìϸ°ûÔö¶àÖ¢£»PB£¬ÍâÖÜѪ¡£aCMLµÄϸ°ûÒÅ´«Ñ§ÌØÕ÷¾¡¹Ü¸ù¾Ý¶¨Ò壬aCMLȱ·¦·Ñ³ÇȾɫÌå¼°BCR-ABL1ÖØÅÅ£¬µ«Ô¼Ò»°ëµÄaCML²¡Àý´æÔÚϸ°ûÒÅ´«Ñ§»û±ä£¬°üÀ¨8ÈýÌå¡¢YȾɫÌåȱʧ¡¢20ºÅȾɫÌ峤±Û²¿·Öȱʧ(20q-)¡¢17ºÅµÈ±ÛȾɫÌå¡¢Éæ¼°12¡¢13¡¢14¡¢17ºÅȾɫÌåµÄȱʧºÍ¸´ÔÓºËÐÍ¡£È»¶øÕâЩϸ°ûÒÅ´«Ñ§Òì³£¾ù·ÇaCMLËùÌØÓУ¬ÇÒÏ൱¶àµÄ²¡Àý£¨¸ß´ï80%£©¿É¾ßÓÐÕý³£µÄºËÐÍ¡£aCMLµÄ¸´·¢ÐÔ»ùÒòÍ»±äaCMLÖÐ×î³£¼ûµÄÍ»±ä»ùÒòÊÇASXL1¡¢NRAS¡¢SETBP1¡¢SRSF2ºÍTET2¡£×î½üÑо¿±íÃ÷£¬69%µÄaCML²¡ÀýÔÚ±í¹ÛÒÅ´«ÐÞÊλùÒòTET2¡¢IDH1/2¡¢DNMT3A¡¢EZH2ºÍ/»òASXL1ÖÐЯ´øÖÁÉÙÒ»ÖÖÍ»±ä¡£Í¼1×ܽáÁËaCMLÖÐ×î³£¼ûµÄÍ»±ä¡£ÈçºÎÕï¶ÏaCMLÕï¶ÏaCMLÓ¦»ùÓÚʶ±ðÆäÌØÕ÷ÐÔµÄÐÎ̬ѧ¡¢ÊµÑéÊÒºÍÒÅ´«Ñ§ÌØÕ÷£¬Åųý¾ßÓÐÃ÷È·ÒÅ´«Ñ§¸Ä±äµÄÆäËûËèϵ¶ñÐÔÖ×Áö¡£³õ²½¼ì²éÓ¦²àÖØÓÚÅųýBCR-ABL1Èںϣ¬¸ù¾Ý¶¨Ò壬CML±ØÈ»´æÔÚBCR-ABL1Èںϣ¬¶øaCMLÖÐÎÞ´ËÏÖÏó¡£»¹Ó¦ÅųýÆäËû²¡ÀíÐÔ»ùÒòÍ»±ä£¬ÈçPDGFRA¡¢PDGFRB¡¢FGFR1£¬»òPCM1-JAK2Èںϡ£¼øÓÚÕâЩÖØÅÅ¿ÉÄÜ´æÔÚÒÅ´«Ñ§ÒþÃØ£¬³ýÁ˺ËÐÍ·ÖÎö£¬ÔÚÈ·¶¨aCMLÕï¶Ï֮ǰ£¬Ó¦¿¼ÂÇFISH¼ì²â»òRNA-²âÐòÀ´ÅųýÉÏÊöÇé¿ö¡£PDGFRBÖØÅŵÄËèϵÖ×Áö»¼Õ߿ɱíÏÖΪMDS/MPNÑù±íÐÍ£¬ÐÎ̬ѧÌØÕ÷ÓëaCMLÏàËÆ¡£ÏÖÒÑÒâʶµ½£¬PDGFRBÖØÅŵÄËèϵÖ×Áö¾ßÓзdz£¹ã·ºµÄ±íÐÍ£¬²¢²»¾ÖÏÞÓÚ°éÊÈËáÐÔÁ£Ï¸°ûÔö¶àÌØÕ÷µÄCMML¡£Ê¶±ðÖØÅÅ£¨ÈçPDGFRB/PDGFRA£©ÖÁ¹ØÖØÒª£¬ÒòΪÓëaCMLÏà±È£¬¾ßÓÐÕâÀàÌØÕ÷µÄ¼²²¡¶ÔÀÒ°±ËἤøÒÖÖƼÁ£¨ÒÁÂíÌæÄᣩµÄÃô¸ÐÐԸߣ¬Ô¤ºó½ÏºÃ¡£Çø·ÖaCMLÓëijЩBCR-ABL1£¨-£©µÄMPNs £¨CNL£¬Ô­·¢ÐÔ¹ÇËèÏËά»¯[PMF]£©ºÍMDS/MPN£¨CMMLºÍMDS/MPN-U£©¾ßÓÐÌôÕ½ÐÔ¡£MPN¼ÈÍùÊ·¿ÉÅųýaCMLµÄÕï¶Ï¡£¹ÇËè»î¼ì·¢ÏÖµäÐ͵ÄMPNÐÎ̬ѧ½á¹û£¨ÓÈÆäÊÇÔÚûÓÐÏÔÖøÁ£Ï¸°û·¢Óý²»Á¼µÄÇé¿öÏ£©ºÍMPNÏà¹ØÍ»±ä£¨ÔÚJAK2¡¢CALR»òMPLÖУ©Ê±£¬²»ÇãÏòaCML£¬ÌáʾPMF¡¢ÕæÐÔºìϸ°ûÔö¶àÖ¢(PV)»òÔ­·¢ÐÔѪС°åÔö¶àÖ¢(ET)¡£ÌáʾÐÔµÄÍ»±äÌØÕ÷£¨ÈçSETBP1/ETNK1Í»±ä£©ÇÒ¾ßÓзûºÏÕï¶Ï±ê×¼µÄÌØÕ÷ÓÐÖúÓÚ֤ʵaCML¡£ÍâÖÜѪÖе¥ºËϸ°ûµÄ°Ù·Ö±ÈÊÇÇø·ÖaCMLºÍCMMLµÄÖØÒªÌØÕ÷£¬ÔÚaCMLÖÐʼÖÕµÍÓÚ10%£¨ºÜÉÙ>2%£©¡£Ï¸°û»¯Ñ§È¾É«£¬Èç·ÇÌØÒìÐÔõ¥Ã¸(NSE)ÓÐÖúÓÚÔÚÒÉÄѲ¡ÀýÖмì²âµ¥ºËϸ°û¡£ÁíÒ»¸ö¸üÖ÷¹ÛµÄÐÎ̬ѧÇø±ðÊÇaCML´æÔÚ¸üÑÏÖصÄÁ£Ï¸°û·¢Óý²»Á¼£¬¾¡¹Üȱ·¦ÆÀ¹À·¢Óý²»Á¼ÑÏÖس̶ȵľßÌåÖ¸ÄÏ¡£ÐèÒª½øÐÐÌúȾɫÒÔÅųý°éÓл·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àµÄMDS/MPN-RS-T¡£ÔÚÒÔÔöÖ³ÌØÕ÷ΪÖ÷£¬ÇÒÒÔÖÐÐÔÁ£Ï¸°ûΪÖ÷µÄ»¼ÕßÖУ¬CSF3RÍ»±äӦǿÁÒÌáʾCNL¡£Çø·ÖaCMLÓëMDS/MPN-U½ÏΪÀ§ÄÑ¡£aCML»¼ÕßµÄÖÐλWBC¼ÆÊýÏÔÖøÉý¸ß£¬µ«·Ç¾ø¶ÔÌØÕ÷¡£³ÖÐøÐÔµ¥ºËϸ°ûÔö¶àÌáʾCMML¡£TET2+SRSF2Í»±ä¶ÔCMML¾ßÓÐÏà¶ÔÌØÒìÐÔ£¬¾¡¹ÜÁ½ÕßÔÚaCMLÖоù¿É¼û¡£Ò»ÖÖеÄaCMLÕï¶ÏÁ÷³ÌС½áÓÉÓÚ·¢²¡Âʵ͡¢Õï¶Ï±ê×¼²»¶Ï¸üкÍȱ·¦·Ö×ÓÒÅ´«Ñ§µÄÀí½â£¬·ÇµäÐÍÂýÐÔËèϵ°×Ѫ²¡Ò»Ö±ÊÇÒ»ÖÖÄÑÒÔÕï¶ÏµÄMDS/MPN¡£Ëæ×ŶԻùÒò×é´óÊý¾ÝµÄ²»¶ÏÍÚ¾ò£¬ÒÑ·¢ÏÖSETBP1ºÍETNK1µÄ·´¸´Í»±ä¶ÔaCMLÓÐÌáʾ×÷Ó㬿ÉÒÔ½áºÏʵÑéÊÒºÍÐÎ̬ѧ½á¹ûÀ´Çø·ÖaCMLºÍÆäËû·Ñ³ÇÒõÐÔ¹ÇËèÔöÖ³ÐÔÖ×Áö¡£È»¶øÍ»±äµÄͬʱ·¢ÉúÊÇ·ñ»á¸Ä±äaCMLµÄ¼²²¡±íÐͺÍÖÎÁÆ·´Ó¦Éв»Ã÷È·¡£²Î¿¼ÎÄÏ×£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.¡°ÕâÊÇÎâÇÙ»­µÄ£¬¡±ÎâÇÙµÄĸÇ×½âÊ͵À£¬ÉùÒôÀï´ø×Åһ˿ϣÍû£¬·Â·ðץסÁË×îºóÒ»¸ù¾ÈÃüµ¾²Ý£¬¡°Ëý˵ÕâÊÇËýÔÚ¸£½¨µÄ¼Ò¡£¡±±ä̬ÉúÀíÑÐÌÖ»á OAD (¶¹°ê)

ÒòΪµ±·¢¶¯»ú¿ªÊ¼ÔËתʱºÜÄÑ׼ȷµØµ÷½ÚÊä³öµÄ¶¯Á¦´óСΪÁ˱£Ö¤³µÁ¾ÔÚ¸÷¸öËÙ¶ÈÇø¼äµÄÎȶ¨ÐÔ±äËÙÏä±»ÒýÈëÆäÖÐ

ÉùÃ÷£º¸ÃÎĹ۵ã½ö´ú±í×÷Õß±¾ÈË£¬ËѺüºÅϵÐÅÏ¢·¢²¼Æ½Ì¨£¬ËѺü½öÌṩÐÅÏ¢´æ´¢¿Õ¼ä·þÎñ¡£